New asthma drug shows promise in reducing severe attacks
NCT ID NCT05593250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called SHR-1905 for people with severe asthma that is not well controlled by current treatments. About 260 adults will receive either the drug or a placebo to see if it reduces asthma attacks and improves breathing and quality of life. The goal is to find a safer and more effective way to manage severe asthma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510163, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?